^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

    Excerpt:
    ...- Patients' tumor sample must have HER2 amplification > 7 based on targeted custom Ampliseq panel on the Ion Torrent Personal Genome Machine (PGM)...
    Trial ID:
    MATCH-Subprotocol Q
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.

    Published date:
    05/16/2018
    Excerpt:
    Various histologies were treated: colon carcinoma (ca) (n = 7), ovarian ca (n = 6), rare tumors such as cholangioca (n = 1), carcinosarcoma of the uterus (n = 1), salivary gland ca (n = 3), among others....T-DM1 was well tolerated. Clinical activity was observed in HER2 amp non breast and gastric/GEJ adenoca pts...
    DOI:
    10.1200/JCO.2018.36.15_suppl.100
    Trial ID:
    NCI-MATCH